UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): December 14, 2009

BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)

 
					
Delaware	 	1-1136	 	22-079-0350	
(State or Other Jurisdiction
of Incorporation)	 	(Commission
File Number)	 	(IRS Employer
Identification Number)	
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant's telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

 

Item 5.02.	Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.	
 
 	(b)(c)	On December 14, 2009, Bristol-Myers Squibb Company (the “Company”), announced the appointment and departure of certain officers as follows:	
 
 	•	 	Jean-Marc Huet, Executive Vice President and Chief Financial Officer, will resign from the Company effective December 31, 2009.	
 
 	•	 	Charles A. Bancroft will be appointed as Acting Chief Financial Officer of the Company, effective January 1, 2010. He will become a member of the Management Council, the Company’s senior-most leadership team. Mr. Bancroft, 50, has worked for the Company for twenty-five (25) years and has held positions of increasing responsibility within the finance organization, including international assignments and senior leadership positions in the global pharmaceutical business. He has been in his current role as Vice President, Finance for Bristol-Myers Squibb’s worldwide pharmaceuticals group since October 2005. From January 2002 until October 2005, Mr. Bancroft served as Vice President, Finance International for Bristol-Myers Squibb’s worldwide pharmaceuticals group.	
There are no arrangements or understandings between Mr. Bancroft and any other persons pursuant to which Mr. Bancroft was selected as an officer. There are no related party transactions between the Company and Mr. Bancroft.
A copy of the press release dated December 14, 2009 announcing Mr. Huet’s departure and Mr. Bancroft’s appointment as Acting Chief Financial Officer is attached hereto as Exhibit 99.1.
 
 	(e)	Effective January 1, 2010 and in connection with Mr. Bancroft’s promotion to Acting Chief Financial Officer of the Company, Mr. Bancroft will receive the following compensation:	
 
 	•	 	An annual base salary of $500,000;	
 
 	•	 	An annual discretionary incentive payment under the Company’s Senior Executive Performance Incentive Plan or any successor annual bonus plan based on a target bonus opportunity of 80% of his base salary based on the attainment of one or more pre-established performance goals established by the Board or a Board Committee;	
 
 	•	 	Participation in the standard annual long-term incentive award program, including eligibility to receive grants of restricted stock units and performance shares, the terms of which will be based on the Company’s standard form of equity award agreements under the Company’s 2007 Stock Award and Incentive Plan; and	
 
 	•	 	Change-in-control benefits in the same form as provided to other Named Executive Officers of the Company.	

Item 9.01.	Financial Statement and Exhibits.	
 
(d)	Exhibits.	

Exhibit No.	  	Description	
		
99.1	  	Press release dated December 14, 2009.	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	 	Bristol-Myers Squibb Company	
			
Dated: December 17, 2009	 	By:	 	/ S /    S ANDRA L EUNG        	
	 	Name:	 	Sandra Leung	
	 	Title:	 	Senior Vice President, General Counsel & Secretary	

EXHIBIT INDEX

Exhibit No.	  	Description	
		
99.1	  	Press release dated December 14, 2009.	

Exhibit 99.1

Bristol-Myers Squibb Announces Appointment of Charles Bancroft
as Acting Chief Financial Officer
(NEW YORK, December 14, 2009) — Bristol-Myers Squibb Company (NYSE:BMY) has appointed Charles Bancroft as acting chief financial officer effective January 1, 2010 and announced that Jean-Marc Huet, executive vice president and chief financial officer, will leave the company at the end of 2009.
“Jean-Marc has indicated to me his desire to return to Europe and we wish him every success,” said James M. Cornelius, chairman and chief executive officer of Bristol-Myers Squibb. “The Board of Directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which have greatly accelerated our BioPharma transformation.”
Bancroft was most recently vice president, finance for Bristol-Myers Squibb’s global biopharmaceutical business. In his new role, Bancroft will continue to report to Lamberto Andreotti, president and chief operating officer.
Bancroft joined Bristol-Myers in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received his B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.
“Charlie has a wide range of technical and operational finance experiences, including strong financial stewardship, business partnering and leadership capabilities which will serve him well in his new role,” said Cornelius. “We have a strong finance team who will maintain our focus on delivering shareholder value.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering,

developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com .
Contacts:
Media: Brian Henry, 609-252-3337, brian.henry@bms.com
Investors: John Elicker, 609-252-4611, john.elicker@bms.com